Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are a subgroup of the superfamily of nuclear receptors, with three distinct main types: α, β and γ (subdivided into γ 1 and γ 2). Recently, the presence of PPARγ has been reported in human islets. Whether other PPAR types can be found in human islets, how islet PPARγ mRNA expression is regulated by the metabolic milieu, their role in insulin secretion, and the effects of a PPARγ agonist are not known. In this study, human pancreatic islets were prepared by collagenase digestion and density gradient purification from nonobese adult donors. The presence of PPAR mRNAs was assessed by RT-PCR, and the effect was evaluated of exposure for up to 24 h to either 22.2 mmol/l glucose and/or 0.25, 0.5, or 1.0 mmol/l long-chain fatty acid mixture (oleate to palmitate, 2:1). PPARβ and, to a greater extent, total PPARγ and PPARγ 2 mRNAs were expressed in human islets, whereas PPARα mRNA was not detected. Compared with human adipose tissue, PPARγ mRNA was expressed at lower levels in the islets, and PPARβ at similar levels. The expression of PPARγ 2 mRNA was not affected by exposure to 22.2 mmol/l glucose, whereas it decreased markedly and time dependently after exposure to progressively higher free fatty acids (FFA). This latter effect was not affected by the concomitant presence of high glucose. Exposure to FFA caused inhibition of insulin mRNA expression, glucose-stimulated insulin release, and reduction of islet insulin content. The PPARγ agonists rosiglitazone and 15-deoxy-Δ-12,14 prostaglandin J 2 prevented the cytostatic effect of FFA as well as the FFA-induced changes of PPAR and insulin mRNA expression. In conclusion, this study shows that PPARγ mRNA is expressed in human pancreatic islets, with predominance of PPARγ 2; exposure to FFA downregulates PPARγ 2 and insulin mRNA expression and inhibits glucose-stimulated insulin secretion; exposure to PPARγ agonists can prevent these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Puigserver, P., & Spiegelman, B. M. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0012 · Cited by 2,076
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812
Zhou, Y. P., & Grill, V. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117042 · Cited by 677 · cited 3×
“The inhibition of insulin release was well expected on the basis of the lipotoxicity concept (17, 23, 27, 36, 40, 50, 51, 52).”
BackgroundPPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612 · cited 1×
“The balance between PPAR and PPAR activities plays a major role in determining cell fat storage (2).”
BackgroundEffects of a 48-h Fat Infusion on Insulin Secretion and Glucose Utilization
Boden, G., Chen, X., Rosner, J., & Barton, M. (1995) · Diabetes · doi:10.2337/diab.44.10.1239 · Cited by 271
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Suppression of β Cell Energy Metabolism and Insulin Release by PGC-1α
Yoon, J. C., Xu, G., Deeney, J. T., Yang, S.-N., Rhee, J., Puigserver, P., Levens, A. R., Yang, R., Zhang, C.-Y., Lowell, B. B., et al. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00170-9 · Cited by 143
Rosati, B., Marchetti, P., Crociani, O., Lecchi, M., Lupi, R., Arcangeli, A., Olivotto, M., & Wanke, E. (2000) · The FASEB Journal · doi:10.1096/fj.00-0077com · Cited by 133
Self-citation
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Sharma, A. M., & Staels, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1268 · Cited by 479
Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes
Del Guerra, S., Lupi, R., Marselli, L., Masini, M., Bugliani, M., Sbrana, S., Torri, S., Pollera, M., Boggi, U., Mosca, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.3.727 · Cited by 466
Self-citationSteneberg, P., Rubins, N., Bartoov-Shifman, R., Walker, M. D., & Edlund, H. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.03.007 · Cited by 411
Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes
Lytrivi, M., Castell, A.-L., Poitout, V., & Cnop, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.09.016 · Cited by 408
Marchetti, P., Del Guerra, S., Marselli, L., Lupi, R., Masini, M., Pollera, M., Bugliani, M., Boggi, U., Vistoli, F., Mosca, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0150 · Cited by 338
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation
Kolb, H., & Mandrup-Poulsen, T. (2010) · Diabetologia · doi:10.1007/s00125-009-1573-7 · Cited by 292
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Henquin, J.-C., Dufrane, D., & Nenquin, M. (2006) · Diabetes · doi:10.2337/db06-0868 · Cited by 228
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
“PPAR is expressed in all three human pancreatic endocrine cell types: , , and (42).”
BackgroundResultDel Prato, S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 197
Self-citationCirculating Levels of Phthalate Metabolites Are Associated With Prevalent Diabetes in the Elderly
Lind, P. M., Zethelius, B., & Lind, L. (2012) · Diabetes Care · doi:10.2337/dc11-2396 · Cited by 188
“PPAR activation has been shown to be involved in different steps in glucose homeostasis, such as influence on insulin resistance (22) and on insulin secretion (32), influence on circulating levels of lipids (21), and altering the amount of visceral and subcutaneous fat (21,33).”
BackgroundMetabolic implications of pancreatic fat accumulation
Wagner, R., Eckstein, S. S., Yamazaki, H., Gerst, F., Machann, J., Jaghutriz, B. A., Schürmann, A., Solimena, M., Singer, S., Königsrainer, A., et al. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00573-3 · Cited by 185
Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly
Lind, L., Zethelius, B., Salihovic, S., van Bavel, B., & Lind, P. M. (2014) · Diabetologia · doi:10.1007/s00125-013-3126-3 · Cited by 128
“For example, it has been shown to influence insulin resistance [25] insulin secretion [26], circulating levels of lipids [26] and the amount of visceral and subcutaneous fat [27, 28].”
BackgroundDo thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
“As suggested by several in vitro studies, a decrease in FFA levels and in circulating inflammatory cytokines should not only alleviate insulin resistance, but also improve β-cell function [35,36].”
BackgroundPinnick, K., Neville, M., Clark, A., & Fielding, B. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22445 · Cited by 55
Effects of rosiglitazone and metformin on pancreatic beta cell gene expression
Richardson, H., Campbell, S. C., Smith, S. A., & Macfarlane, W. M. (2006) · Diabetologia · doi:10.1007/s00125-006-0155-1 · Cited by 34
Glucose plus metformin compared with glucose alone on β-cell function in mouse pancreatic islets
HASHEMITABAR, M., BAHRAMZADEH, S., SAREMY, S., & NEJADDEHBASHI, F. (2015) · Biomedical Reports · doi:10.3892/br.2015.476 · Cited by 21
Metadata
- Authors
- Lupi, R., Del Guerra, S., Marselli, L., Bugliani, M., Boggi, U., Mosca, F., Marchetti, P., & Del Prato, S.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2004-04
- Volume
- 286
- Issue
- 4
- Pages
- E560-E567
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2158031531
- Cited by
- 152
- References
- 10
- FWCI
- 15.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.